Introduction: The real-world experience on treatment and outcome of hemophilics with extended half-life products is scarce due to the rarity of the disease and poor access to newer treatment modalities. Aim: To analyze the response of patients with severe hemophilia A and B with severe arthropathy on Extended Half Life factor (EHL) prophylaxis. Methods: Patients with severe Hemophilia A and B with access to prophylaxis with extended half-life factor concentrates at our centre were included in this analysis. Bleed frequency, joint involvement, number of hospital visits and Hemophilia Joint Health Score (HJHS) were documented before and after to switching from standard half-life on-demand treatment to extended half-life prophylaxis Results: 31 patients were initiated on EHL-prophylaxis and followed up during the study period ranging from 4 to 91 weeks. There was reduction in the annualized bleed rate and improvement in HJHS during this period. Patients also demonstrated reversal in target joints and bleed-related compression neuropathy. Conclusion: EHL prophylaxis is an effective strategy even in patients with baseline target joints with significant morbidity.
